Ardelyx appoints Mark Kaufmann as chief business officer
Role includes business development, licensing and strategic planning
Kaufmann was formerly chief executive of Allostera and Celmed BioSciences.
‘Mark’s deep understanding of the biotechnology business, coupled with his substantial experience at the most senior levels in business development and planning will serve Ardelyx well during our next phase of corporate development,’ said Mike Raab, chairman and ceo of Ardelyx.
Kaufmann has more than 20 years of experience in the biopharmaceutical industry in the US and Canada in business and corporate development roles.
Most recently, he was president and ceo of Allostera Pharma, a venture-backed, preclinical company focused on autoimmune diseases.
Prior to joining Allostera, Kaufmann was president and ceo of Celmed BioSciences, where he was responsible for raising funds and selling the company to Kiadis Pharma, a European biotechnology company. He has also held roles at Nexia Biotechnologies, Conceptis Technologies and MedImmune.
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment
AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy